DIACOMIT is the only FDA-approved antiseizure medication specifically for seizures associated with Dravet syndrome in children as young as 6 months. It is indicated for patients weighing 15 pounds or more and taking clobazam.
DIACOMIT® (stiripentol) is an effective, FDA-approved medication that was developed specifically to treat seizures associated with Dravet syndrome. It is indicated for patients 6 months and older (weighing 15 lb or more) taking clobazam. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.1
DIACOMIT may help patients achieve profound seizure reduction so families can celebrate everyday wins.1
Explore our expanding list of resources designed to equip you with tools and research to help inform your treatment decisions. Want a physical copy? You can request free printed materials for your office below.
DIACOMIT has over three decades of patient exposure and extensive data collection.7,36,37,51
Download this guide for information on studies illustrating DIACOMIT’s efficacy and safety profile.
Download GuideKeep this list handy to check the documented and potential drug interactions with DIACOMIT.
Download CardReference this guide to calculating the proper dose of DIACOMIT for your patients.
Download CardDIACOMIT may help patients with Dravet achieve profound seizure reduction so families can celebrate everyday wins. See what makes DIACOMIT different.
Download GuideReview the trial designs for DIACOMIT’s two clinical studies.
Download CardSee how DIACOMIT is thought to interact with GABAA receptors and cytochrome P450 enzymes. The exact mechanism by which DIACOMIT exerts its anticonvulsant effect in humans is unknown.
Hear from Dravet syndrome expert physicians about their DIACOMIT experience.
DIACOMIT reduced seizures for Dr. Wheless’ patient, allowing him to reduce his patient’s overall medication burden.
Pediatric epileptologist Dr. Sullivan details his 10-year journey with a patient with Dravet syndrome — and how DIACOMIT has substantially reduced his patient’s seizures.
Caregivers share their children’s Dravet diagnosis and DIACOMIT treatment journeys.
Tatiana’s journey to get her daughter properly diagnosed with Dravet syndrome was challenging. Learn how Eliana’s family worked tirelessly to find an effective seizure treatment for her.
Duane and Daryl, Julia’s parents, share how DIACOMIT has made a substantial difference for their daughter.
Follow Kendall’s long-term seizure management journey with DIACOMIT as told by her mother and caregiver, Jill.
Download forms or letters needed to complete payer requests.
Download this guide for a quick overview of our three-step access process through our specialty pharmacy.
Download Access GuideKeep track of required forms and information needed to fill prescriptions with our specialty pharmacy.
Download Access ChecklistFill out this form with your patient’s information to get them access to DIACOMIT.
Download Enrollment FormIf your patient uses U.S. Department of Veterans Affairs (VA) health insurance, fill out this form to get them access to DIACOMIT.
Download VA FormCustomize this letter to appeal a denied prior authorization request, formulary exception, or claim for DIACOMIT.
Download Letter of AppealEdit this letter to provide additional information and explanation for a patient to begin treatment with DIACOMIT.
Download Letter of Medical NecessityShare information about Dravet syndrome and DIACOMIT with patients and their caregivers.
An educational resource developed with the Dravet Syndrome Foundation and Dravet physician experts. It equips parents and caregivers of children with Dravet syndrome with information about this rare disease.
Download Information BookletA quick overview of DIACOMIT, including seizure reduction results, convenient dosing information, and access programs.
Download Caregiver’s GuideA story for siblings of children with Dravet syndrome inspired by actual families and their experiences.
Download Comic Book
